VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VOR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HomeStocksVORInstitutional Holders

VOR logoVor Biopharma Inc. (VOR) Institutional Ownership

Q2 2026 13F Data|Updated 2026-11-18

✨

Institutional ownership increased this quarter (+12.98 pp), though top 10 holders maintain a highly concentrated 67.6% of institutional value.

Institutional Ownership
Can exceed 100% due to securities lending, short interest, and reporting timing differences.
81.4%$893M total value · ▲ +12.98 pp vs prior quarter
Smart Money Score
Based on ownership concentration, fund quality, buying/selling activity, ownership indicators, and institutional trend.
65 / 100Bullish
Institutions & Flow102 holders+21 net flow (+38 / -17)

AI Insights & Key Takeaways

  • Positive Institutional Flow (+21)
  • Millennium Management Llc maintains a significant position
  • Top 10 holders control 67.6% of institutional value
  • No Insider Signal

Top Institutional Holders of VOR

Ranked by reported Q2 2026 13F market value

Top 10 Holders
67.6%
Top 25 Holders
91.8%

Share of total reported institutional value in VOR held by the largest 10 / 25 filers.

#InstitutionShares HeldMarket ValueQoQ ChangeOwnership %% of Fund
1TCG Crossover Management, LLC5.7M$104.4M0.0%9.508%2.51%
2FMR LLC4.9M$90.8M+220.3%8.266%0.00%
3FCPM III SERVICES B.V.4.1M$75.8M0.0%6.900%10.10%

Quarterly Institutional Activity

Filings activity in VOR during Q2 2026, grouped by how each filer changed its position.

OverviewNew Buyers38Added To45Trimmed18Exited17
  • RA CAPITAL MANAGEMENT, L.P.$44.2M
  • NEXTBio Capital Management LP$16.4M

VOR Institutional Ownership by Quarter

4 quarters of 13F filings · Δ columns show change vs prior quarter

QuarterInst. HoldersΔ HoldersOwnership %Δ OwnershipTotal 13F ValueΔ Value
Q2 2026102+28%81.40%+12.98 pp$893M+24%
Q1 202680+43%68.42%+18.59 pp$720M+105%
Q4 202556+40%49.83%+30.84 pp$350M29%
Q3 202540—18.99%—$496M—

Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.

How VOR Compares to Peers

Institutional ownership and quarterly buying activity across the largest Immunology Biotech peers.

TickerCompanyMarket CapInst. OwnershipHoldersNet Buyers − Sellers
LKFTLakefront Biotherapeutics N.V.$2.19B49.6%79-12
YARWYarrow Bioscience Inc$145M1.2%47+2
RKTORocket One Inc.$9M7.9%22+3

VOR — Frequently Asked Questions

Quick answers to the most common questions about buying VOR stock.

What percentage of VOR is owned by institutions?

Based on Q2 2026 13F filings, institutional ownership of Vor Biopharma Inc. stands at 81.4%, held across 102 reporting institutions.

Who is the largest institutional holder of VOR?

TCG Crossover Management, LLC is the largest reported institutional holder of VOR, with approximately 5,673,078 shares worth $0.10B as of Q2 2026.

Is VOR a hedge fund favorite?

Yes — 1 widely-followed marquee investor appear among the top 25 institutional holders of VOR, including MILLENNIUM MANAGEMENT LLC.

What is VOR's Smart Money Score?

Our composite Smart Money Score for VOR is 65 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.

How many institutions bought VOR this quarter?

38 institutions opened new positions in VOR during Q2 2026, while 17 fully exited. 45 added to existing positions and 18 trimmed.

4
BlackRock, Inc.
3.5M
$63.8M
+336.4%
5.812%
0.00%
5Venrock Adviser, LLC3.0M$56.0M0.0%5.098%1.70%
6STATE STREET CORP2.6M$48.2M+133.9%4.385%0.00%
7Frazier Life Sciences Management, L.P.2.5M$46.8M0.0%4.263%1.02%
8RA CAPITAL MANAGEMENT, L.P.2.4M$44.2M-55.6%4.026%0.38%
9VANGUARD CAPITAL MANAGEMENT LLC2.1M$38.4M+45.4%3.493%0.00%
10Caligan Partners LP1.9M$35.4M0.0%3.226%1.67%
11Paradigm Biocapital Advisors LP1.8M$32.2M0.0%2.933%0.60%
12GREAT POINT PARTNERS LLC1.7M$31.3M-2.9%2.849%5.91%
13GEODE CAPITAL MANAGEMENT, LLC1.1M$19.6M+210.1%1.781%0.00%
14NEXTBio Capital Management LP889K$16.4M-11.1%1.490%7.53%
15Nantahala Capital Management, LLC845K$15.6M—1.416%0.26%
16ADAR1 Capital Management, LLC681K$12.5M—1.141%0.57%
17Logos Global Management LP650K$12.0M-13.3%1.089%0.52%
18Rosalind Advisors, Inc.649K$11.9M-7.3%1.087%4.44%
19NAN FUNG TRINITY (HK) Ltd647K$11.9M—1.083%1.18%
20BRAIDWELL LP573K$10.6M+22.8%0.961%0.39%
21BOOTHBAY FUND MANAGEMENT, LLC559K$10.3M+0.5%0.936%0.14%
22UBS Group AG493K$9.1M+1.0%0.827%0.00%
23MILLENNIUM MANAGEMENT LLC428K$7.9M+65.5%0.717%0.00%
24SPHERA FUNDS MANAGEMENT LTD.416K$7.7M+29.4%0.698%1.00%
25Woodline Partners LP380K$7.0M—0.636%0.02%

denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in VOR — a direct measure of their conviction.

Logos Global Management LP
$12.0M
  • Rosalind Advisors, Inc.$11.9M
  • Clearline Capital LP$5.3M
  • MARSHALL WACE, LLP$1.8M
  • AXIOM INVESTORS LLC /DE$1.7M
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP$1.5M
  • Jump Financial, LLC$1.3M
  • MORGAN STANLEY$1.1M
  • Rafferty Asset Management, LLC$899K
  • RENAISSANCE TECHNOLOGIES LLC$608K
  • How is institutional ownership of VOR changing?

    VOR institutional ownership rose by 12.98 percentage points quarter-over-quarter, with a net change of +22 holders.

    How concentrated is VOR ownership among the top holders?

    The top 10 institutions account for 67.6% of all reported 13F value in VOR, and the top 25 account for 91.8%.

    How does VOR compare to Immunology Biotech on institutional ownership?

    Across the largest Immunology Biotech peers, institutional ownership levels are: LKFT (49.6%), YARW (1.2%), RKTO (7.9%). See the peer comparison table on this page for net buyer activity by company.

    Where does this VOR institutional ownership data come from?

    All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.

    VORVor Biopharma Inc.
    $17.83$1.1B
    Overview & Tools
    OverviewChart Terminal ↗Visualize
    Valuation & Forecasts
    Valuation ModelsEstimatesDCF Model
    Price & Analyst Data
    Analyst TargetsPrice History
    Financial Statements
    Income StatementBalance SheetCash FlowRatios & Margins
    Performance
    P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
    Discovery & Screens
    Live BreakoutsStock ScreenerOwnership